Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Encephalitis l: Introduction

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026

Same author

Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.

Gut microbes·2026

Same author

Prion propagation is controlled by a hierarchical network involving the nuclear Tfap2c and hnRNP K factors and the cytosolic mTORC1 complex.

PLoS pathogens·2026

Same author

Large-scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation.

FEBS open bio·2026

Same author

Structure-function relationship of alpha-synuclein fibrillar polymorphs derived from distinct synucleinopathies.

Molecular systems biology·2026

Same author

Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: May 5, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

Experimental autoimmune encephalomyelitis repressed by microglial paralysis.

Frank L Heppner¹, Melanie Greter, Denis Marino

¹Institute of Neuropathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Nature Medicine

|January 25, 2005

Summary

Targeting microglia, the immune cells of the central nervous system (CNS), can halt inflammatory CNS diseases. This study validates CD11b-HSVTK mice as a tool to explore microglial roles in CNS disorders.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Related Experiment Videos

Last Updated: May 5, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Area of Science:

Neuroimmunology
Central Nervous System (CNS) Disorders
Cellular Biology

Background:

Microglial activation is observed in various CNS disorders, but its precise role in disease pathogenesis remains unclear.
Understanding microglial function is crucial for developing targeted therapies for inflammatory CNS conditions.

Purpose of the Study:

To investigate the role of microglial activation in the pathogenesis of inflammatory central nervous system (CNS) disorders.
To validate CD11b-HSVTK transgenic mice as a model for studying microglial function in CNS diseases.

Main Methods:

Generation of CD11b-HSVTK transgenic mice expressing herpes simplex thymidine kinase in macrophages and microglia.
Treatment with ganciclovir to selectively eliminate or inhibit microglia.
Analysis of microglial activation markers and inflammatory responses in brain slice cultures and in vivo models (axotomy, experimental autoimmune encephalomyelitis).
Bone marrow chimera experiments to assess hematopoietic toxicity and microglial-specific effects.

Main Results:

Ganciclovir treatment abolished microglial release of inflammatory mediators (nitrite, cytokines, chemokines) in vitro.
Systemic ganciclovir administration in CD11b-HSVTK mice led to hematopoietic toxicity, preventable by wild-type bone marrow transfer.
Ganciclovir administration in bone marrow chimeras blocked microglial activation post-axotomy and repressed experimental autoimmune encephalomyelitis development.
Microglial paralysis effectively inhibited the development and maintenance of inflammatory CNS lesions.

Conclusions:

Microglial activation plays a significant role in the development and progression of inflammatory CNS disorders.
Targeting the microglial compartment offers a potential therapeutic strategy for inflammatory CNS diseases.
CD11b-HSVTK mice serve as a valuable tool for in vivo studies on the impact of microglial activation in CNS pathology.